Abstract | BACKGROUND: METHODS: Colon tissue from human patients with UC with active disease or in remission with or without vedolizumab treatment was stained by immunohistochemistry. We reconstituted NOD-SCID-SGM3 mice with human CD34+ cells and treated them with dextran sodium sulfate to induce acute colitis. Mice were treated with vedolizumab alone, or in combination with tacrolimus, ozanimid, or tofacitinib. RESULTS: CONCLUSIONS: Our data show that vedolizumab reduces the number of innate and adaptive immune cells in the mucosa of patients with UC. Further, the combination of vedolizumab with tacrolimus was more efficient to reduce immune cell numbers and to increase therapeutic efficacy than vedolizumab monotreatment. This finding indicates that combination treatment using these two drugs may be beneficial for patients who do not respond to vedolizumab monotherapy.
|
Authors | Roberto Manzini, Marlene Schwarzfischer, Kirstin Atrott, Andrea Laimbacher, Silvia Lang, Marcin Wawrzyniak, Andreas Rickenbacher, Matthias Turina, Petr Hruz, Donata Lissner, Britta Siegmund, Gerhard Rogler, Michael Scharl, Marianne R Spalinger |
Journal | Inflammatory bowel diseases
(Inflamm Bowel Dis)
Vol. 27
Issue 12
Pg. 1986-1998
(11 15 2021)
ISSN: 1536-4844 [Electronic] England |
PMID | 33847343
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected]. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Dextrans
- Gastrointestinal Agents
- Immunomodulating Agents
- vedolizumab
- Tacrolimus
|
Topics |
- Animals
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Colitis, Ulcerative
(chemically induced, drug therapy)
- Dextrans
- Gastrointestinal Agents
(therapeutic use)
- Humans
- Immunomodulating Agents
- Inflammation
(drug therapy)
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Tacrolimus
(therapeutic use)
- Treatment Outcome
|